FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) — Geron Company (Nasdaq: GERN), a advertisement level biopharmaceutical corporate, as of late reported that it granted an fairness award within the type of a inventory choice to buy 2,500,000 stocks of Geron commonplace inventory to Timothy Williams, Geron’s new Govt Vice President, Leader Felony Officer and Company Secretary, as an inducement subject matter to his acceptance of employment with Geron.
The inventory choice was once granted on April 13, 2026. The inventory choice has an workout value of $1.73 consistent with proportion, which is the same as the ultimate value of Geron’s commonplace inventory at the grant date, has a ten-year time period and vests over 4 years, with 12.5% of the stocks underlying the choice vesting at the six-month anniversary of graduation of his employment and the remainder stocks vesting over the next 42 months in equivalent installments of entire stocks, topic to endured carrier with Geron in the course of the appropriate vesting dates.
The inventory choice grant was once authorized via the Reimbursement Committee of Geron’s Board of Administrators in response to Nasdaq List Rule 5635(c)(4) and is topic to the phrases and stipulations of Geron’s 2018 Inducement Award Plan and the type of inventory choice settlement below that plan.
About Geron Geron is a commercial-stage biopharmaceutical corporate aiming to switch lives via converting the process blood most cancers. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is authorized in the USA and the Ecu Union for the remedy of positive grownup sufferers with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We also are accomplishing a pivotal Segment 3 scientific trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, in addition to research in different hematologic malignancies. Inhibiting telomerase process, which is higher in malignant stem and progenitor cells within the bone marrow, targets to doubtlessly scale back proliferation and induce dying of malignant cells. To be informed extra, discuss with www.geron.com or observe us on LinkedIn.
